nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—DRD5—eyelid—head and neck cancer	0.0543	0.134	CbGeAlD
Loxapine—HTR7—superior cervical ganglion—head and neck cancer	0.0335	0.0825	CbGeAlD
Loxapine—HTR1B—trigeminal nerve—head and neck cancer	0.0245	0.0605	CbGeAlD
Loxapine—HTR1D—trigeminal nerve—head and neck cancer	0.0238	0.0585	CbGeAlD
Loxapine—HTR3A—cranial nerve—head and neck cancer	0.0208	0.0513	CbGeAlD
Loxapine—Ileus paralytic—Vinblastine—head and neck cancer	0.0197	0.0552	CcSEcCtD
Loxapine—HRH1—nose—head and neck cancer	0.018	0.0444	CbGeAlD
Loxapine—HTR1B—cranial nerve—head and neck cancer	0.0175	0.0431	CbGeAlD
Loxapine—HTR1D—cranial nerve—head and neck cancer	0.0169	0.0417	CbGeAlD
Loxapine—HTR7—cranial nerve—head and neck cancer	0.0135	0.0332	CbGeAlD
Loxapine—Slurred speech—Fluorouracil—head and neck cancer	0.0125	0.0351	CcSEcCtD
Loxapine—HTR2A—trigeminal nerve—head and neck cancer	0.0118	0.0291	CbGeAlD
Loxapine—HTR5A—head—head and neck cancer	0.0105	0.0259	CbGeAlD
Loxapine—Numbness—Vinblastine—head and neck cancer	0.0103	0.0288	CcSEcCtD
Loxapine—Sensory loss—Vinblastine—head and neck cancer	0.00982	0.0276	CcSEcCtD
Loxapine—Amenorrhoea—Hydroxyurea—head and neck cancer	0.00883	0.0248	CcSEcCtD
Loxapine—Chest tightness—Docetaxel—head and neck cancer	0.0086	0.0241	CcSEcCtD
Loxapine—HTR2A—cranial nerve—head and neck cancer	0.00841	0.0207	CbGeAlD
Loxapine—Menstruation irregular—Docetaxel—head and neck cancer	0.00728	0.0204	CcSEcCtD
Loxapine—Numbness—Fluorouracil—head and neck cancer	0.00674	0.0189	CcSEcCtD
Loxapine—Sensory loss—Fluorouracil—head and neck cancer	0.00645	0.0181	CcSEcCtD
Loxapine—CHRM3—exocrine gland—head and neck cancer	0.00638	0.0157	CbGeAlD
Loxapine—Cerebrovascular accident—Vinblastine—head and neck cancer	0.0063	0.0177	CcSEcCtD
Loxapine—Dysarthria—Fluorouracil—head and neck cancer	0.00591	0.0166	CcSEcCtD
Loxapine—CHRM5—epithelium—head and neck cancer	0.00496	0.0122	CbGeAlD
Loxapine—Photosensitivity—Fluorouracil—head and neck cancer	0.00462	0.013	CcSEcCtD
Loxapine—Amenorrhoea—Docetaxel—head and neck cancer	0.00459	0.0129	CcSEcCtD
Loxapine—Chest discomfort—Docetaxel—head and neck cancer	0.00456	0.0128	CcSEcCtD
Loxapine—HTR7—mouth—head and neck cancer	0.00454	0.0112	CbGeAlD
Loxapine—HTR1E—head—head and neck cancer	0.0045	0.0111	CbGeAlD
Loxapine—Agranulocytosis—Vinblastine—head and neck cancer	0.00444	0.0125	CcSEcCtD
Loxapine—Weight increased—Hydroxyurea—head and neck cancer	0.00443	0.0124	CcSEcCtD
Loxapine—Drowsiness—Hydroxyurea—head and neck cancer	0.00434	0.0122	CcSEcCtD
Loxapine—DRD5—lymphoid tissue—head and neck cancer	0.00426	0.0105	CbGeAlD
Loxapine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00425	0.0119	CcSEcCtD
Loxapine—Hepatocellular injury—Docetaxel—head and neck cancer	0.00403	0.0113	CcSEcCtD
Loxapine—CHRM4—head—head and neck cancer	0.00394	0.00971	CbGeAlD
Loxapine—HTR7—neck—head and neck cancer	0.00388	0.00957	CbGeAlD
Loxapine—Alopecia—Vinblastine—head and neck cancer	0.00378	0.0106	CcSEcCtD
Loxapine—CHRM1—parotid gland—head and neck cancer	0.00371	0.00915	CbGeAlD
Loxapine—DRD3—head—head and neck cancer	0.00366	0.00903	CbGeAlD
Loxapine—Lightheadedness—Docetaxel—head and neck cancer	0.00361	0.0101	CcSEcCtD
Loxapine—CHRM1—saliva-secreting gland—head and neck cancer	0.00356	0.00876	CbGeAlD
Loxapine—Angiopathy—Hydroxyurea—head and neck cancer	0.00354	0.00992	CcSEcCtD
Loxapine—HTR6—head—head and neck cancer	0.00353	0.00869	CbGeAlD
Loxapine—Dysphagia—Fluorouracil—head and neck cancer	0.0035	0.00984	CcSEcCtD
Loxapine—HTR1D—connective tissue—head and neck cancer	0.00349	0.00861	CbGeAlD
Loxapine—Alopecia—Hydroxyurea—head and neck cancer	0.00344	0.00967	CcSEcCtD
Loxapine—DRD5—head—head and neck cancer	0.00343	0.00846	CbGeAlD
Loxapine—ADRB1—connective tissue—head and neck cancer	0.0034	0.00836	CbGeAlD
Loxapine—Leukopenia—Vinblastine—head and neck cancer	0.00333	0.00935	CcSEcCtD
Loxapine—HRH2—head—head and neck cancer	0.00323	0.00794	CbGeAlD
Loxapine—Convulsion—Vinblastine—head and neck cancer	0.00322	0.00905	CcSEcCtD
Loxapine—Hypertension—Vinblastine—head and neck cancer	0.00321	0.00902	CcSEcCtD
Loxapine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.0032	0.00898	CcSEcCtD
Loxapine—CHRM3—saliva-secreting gland—head and neck cancer	0.00318	0.00784	CbGeAlD
Loxapine—CHRM5—head—head and neck cancer	0.00308	0.00759	CbGeAlD
Loxapine—Leukopenia—Hydroxyurea—head and neck cancer	0.00304	0.00852	CcSEcCtD
Loxapine—Thrombocytopenia—Vinblastine—head and neck cancer	0.00297	0.00834	CcSEcCtD
Loxapine—Convulsion—Hydroxyurea—head and neck cancer	0.00294	0.00825	CcSEcCtD
Loxapine—Agranulocytosis—Fluorouracil—head and neck cancer	0.00292	0.00819	CcSEcCtD
Loxapine—ADRA2C—parotid gland—head and neck cancer	0.00291	0.00716	CbGeAlD
Loxapine—ADRA1B—head—head and neck cancer	0.00282	0.00693	CbGeAlD
Loxapine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00279	0.00783	CcSEcCtD
Loxapine—HTR7—connective tissue—head and neck cancer	0.00278	0.00686	CbGeAlD
Loxapine—Oedema—Hydroxyurea—head and neck cancer	0.00277	0.00777	CcSEcCtD
Loxapine—CHRM1—trachea—head and neck cancer	0.00274	0.00676	CbGeAlD
Loxapine—Paraesthesia—Vinblastine—head and neck cancer	0.00273	0.00765	CcSEcCtD
Loxapine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00272	0.00762	CcSEcCtD
Loxapine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00271	0.00761	CcSEcCtD
Loxapine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00267	0.0075	CcSEcCtD
Loxapine—HTR7—epithelium—head and neck cancer	0.00264	0.00651	CbGeAlD
Loxapine—DRD1—head—head and neck cancer	0.00262	0.00646	CbGeAlD
Loxapine—Constipation—Vinblastine—head and neck cancer	0.0026	0.00729	CcSEcCtD
Loxapine—ADRA1A—epithelium—head and neck cancer	0.00255	0.00628	CbGeAlD
Loxapine—HTR3A—head—head and neck cancer	0.00253	0.00624	CbGeAlD
Loxapine—Dysphagia—Docetaxel—head and neck cancer	0.00253	0.0071	CcSEcCtD
Loxapine—Feeling abnormal—Vinblastine—head and neck cancer	0.0025	0.00702	CcSEcCtD
Loxapine—Bronchospasm—Docetaxel—head and neck cancer	0.00249	0.00698	CcSEcCtD
Loxapine—Alopecia—Fluorouracil—head and neck cancer	0.00248	0.00696	CcSEcCtD
Loxapine—Dyspnoea—Hydroxyurea—head and neck cancer	0.00247	0.00693	CcSEcCtD
Loxapine—Somnolence—Hydroxyurea—head and neck cancer	0.00246	0.00691	CcSEcCtD
Loxapine—HTR2A—neck—head and neck cancer	0.00242	0.00596	CbGeAlD
Loxapine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00239	0.00671	CcSEcCtD
Loxapine—Fatigue—Hydroxyurea—head and neck cancer	0.00239	0.0067	CcSEcCtD
Loxapine—Constipation—Hydroxyurea—head and neck cancer	0.00237	0.00665	CcSEcCtD
Loxapine—HTR7—trachea—head and neck cancer	0.00234	0.00576	CbGeAlD
Loxapine—Weight increased—Docetaxel—head and neck cancer	0.0023	0.00646	CcSEcCtD
Loxapine—Vision blurred—Fluorouracil—head and neck cancer	0.0023	0.00646	CcSEcCtD
Loxapine—Weight decreased—Docetaxel—head and neck cancer	0.00229	0.00642	CcSEcCtD
Loxapine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00228	0.0064	CcSEcCtD
Loxapine—HRH2—lymph node—head and neck cancer	0.00226	0.00556	CbGeAlD
Loxapine—Hypersensitivity—Vinblastine—head and neck cancer	0.00224	0.00628	CcSEcCtD
Loxapine—Renal failure—Docetaxel—head and neck cancer	0.00222	0.00622	CcSEcCtD
Loxapine—Jaundice—Docetaxel—head and neck cancer	0.0022	0.00617	CcSEcCtD
Loxapine—Leukopenia—Fluorouracil—head and neck cancer	0.00219	0.00614	CcSEcCtD
Loxapine—Asthenia—Vinblastine—head and neck cancer	0.00218	0.00611	CcSEcCtD
Loxapine—ADRA2C—trachea—head and neck cancer	0.00215	0.00529	CbGeAlD
Loxapine—HTR1B—head—head and neck cancer	0.00213	0.00524	CbGeAlD
Loxapine—Convulsion—Fluorouracil—head and neck cancer	0.00212	0.00594	CcSEcCtD
Loxapine—CHRM2—head—head and neck cancer	0.00211	0.00521	CbGeAlD
Loxapine—SLC6A3—head—head and neck cancer	0.00211	0.00519	CbGeAlD
Loxapine—Agranulocytosis—Docetaxel—head and neck cancer	0.0021	0.00591	CcSEcCtD
Loxapine—Chest pain—Fluorouracil—head and neck cancer	0.00208	0.00584	CcSEcCtD
Loxapine—HRH1—connective tissue—head and neck cancer	0.00208	0.00512	CbGeAlD
Loxapine—HTR1D—head—head and neck cancer	0.00206	0.00507	CbGeAlD
Loxapine—ADRA2A—connective tissue—head and neck cancer	0.00204	0.00503	CbGeAlD
Loxapine—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00204	0.00573	CcSEcCtD
Loxapine—HTR2C—head—head and neck cancer	0.00204	0.00502	CbGeAlD
Loxapine—Hepatitis—Docetaxel—head and neck cancer	0.00202	0.00568	CcSEcCtD
Loxapine—Hypoaesthesia—Docetaxel—head and neck cancer	0.00201	0.00565	CcSEcCtD
Loxapine—Confusional state—Fluorouracil—head and neck cancer	0.00201	0.00564	CcSEcCtD
Loxapine—Dizziness—Vinblastine—head and neck cancer	0.00201	0.00564	CcSEcCtD
Loxapine—ADRB1—head—head and neck cancer	0.002	0.00493	CbGeAlD
Loxapine—Oedema—Fluorouracil—head and neck cancer	0.00199	0.00559	CcSEcCtD
Loxapine—Asthenia—Hydroxyurea—head and neck cancer	0.00199	0.00558	CcSEcCtD
Loxapine—HRH1—epithelium—head and neck cancer	0.00197	0.00486	CbGeAlD
Loxapine—ADRA1A—lymphoid tissue—head and neck cancer	0.00196	0.00484	CbGeAlD
Loxapine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00195	0.00549	CcSEcCtD
Loxapine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00195	0.00548	CcSEcCtD
Loxapine—Tachycardia—Fluorouracil—head and neck cancer	0.00195	0.00546	CcSEcCtD
Loxapine—CHRM3—thyroid gland—head and neck cancer	0.00194	0.00478	CbGeAlD
Loxapine—SLC6A4—head—head and neck cancer	0.00193	0.00476	CbGeAlD
Loxapine—Vomiting—Vinblastine—head and neck cancer	0.00193	0.00542	CcSEcCtD
Loxapine—CHRM1—head—head and neck cancer	0.00193	0.00474	CbGeAlD
Loxapine—Headache—Vinblastine—head and neck cancer	0.0019	0.00534	CcSEcCtD
Loxapine—Hypotension—Fluorouracil—head and neck cancer	0.00186	0.00523	CcSEcCtD
Loxapine—Angiopathy—Docetaxel—head and neck cancer	0.00184	0.00516	CcSEcCtD
Loxapine—Dizziness—Hydroxyurea—head and neck cancer	0.00183	0.00514	CcSEcCtD
Loxapine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00182	0.00512	CcSEcCtD
Loxapine—Nausea—Vinblastine—head and neck cancer	0.0018	0.00506	CcSEcCtD
Loxapine—Insomnia—Fluorouracil—head and neck cancer	0.0018	0.00506	CcSEcCtD
Loxapine—Paraesthesia—Fluorouracil—head and neck cancer	0.00179	0.00502	CcSEcCtD
Loxapine—Alopecia—Docetaxel—head and neck cancer	0.00179	0.00502	CcSEcCtD
Loxapine—Dyspnoea—Fluorouracil—head and neck cancer	0.00178	0.00499	CcSEcCtD
Loxapine—Somnolence—Fluorouracil—head and neck cancer	0.00177	0.00497	CcSEcCtD
Loxapine—Vomiting—Hydroxyurea—head and neck cancer	0.00176	0.00494	CcSEcCtD
Loxapine—Rash—Hydroxyurea—head and neck cancer	0.00175	0.0049	CcSEcCtD
Loxapine—HRH1—trachea—head and neck cancer	0.00174	0.0043	CbGeAlD
Loxapine—Dermatitis—Hydroxyurea—head and neck cancer	0.00174	0.0049	CcSEcCtD
Loxapine—HTR2A—connective tissue—head and neck cancer	0.00174	0.00428	CbGeAlD
Loxapine—Headache—Hydroxyurea—head and neck cancer	0.00173	0.00487	CcSEcCtD
Loxapine—Dysgeusia—Docetaxel—head and neck cancer	0.00173	0.00484	CcSEcCtD
Loxapine—CHRM3—head—head and neck cancer	0.00172	0.00424	CbGeAlD
Loxapine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00172	0.00483	CcSEcCtD
Loxapine—HTR1A—head—head and neck cancer	0.00172	0.00423	CbGeAlD
Loxapine—ADRA2A—trachea—head and neck cancer	0.00171	0.00422	CbGeAlD
Loxapine—SLC6A2—head—head and neck cancer	0.0017	0.00419	CbGeAlD
Loxapine—Muscle spasms—Docetaxel—head and neck cancer	0.00169	0.00476	CcSEcCtD
Loxapine—HTR2A—epithelium—head and neck cancer	0.00165	0.00406	CbGeAlD
Loxapine—Nausea—Hydroxyurea—head and neck cancer	0.00164	0.00462	CcSEcCtD
Loxapine—Feeling abnormal—Fluorouracil—head and neck cancer	0.00164	0.00461	CcSEcCtD
Loxapine—HTR7—head—head and neck cancer	0.00164	0.00404	CbGeAlD
Loxapine—ADRA1A—head—head and neck cancer	0.00158	0.0039	CbGeAlD
Loxapine—Syncope—Docetaxel—head and neck cancer	0.00158	0.00444	CcSEcCtD
Loxapine—Leukopenia—Docetaxel—head and neck cancer	0.00158	0.00443	CcSEcCtD
Loxapine—DRD2—head—head and neck cancer	0.00155	0.00382	CbGeAlD
Loxapine—Loss of consciousness—Docetaxel—head and neck cancer	0.00155	0.00435	CcSEcCtD
Loxapine—Cough—Docetaxel—head and neck cancer	0.00154	0.00432	CcSEcCtD
Loxapine—Convulsion—Docetaxel—head and neck cancer	0.00153	0.00429	CcSEcCtD
Loxapine—Hypertension—Docetaxel—head and neck cancer	0.00152	0.00427	CcSEcCtD
Loxapine—ADRA2C—head—head and neck cancer	0.00151	0.00371	CbGeAlD
Loxapine—Chest pain—Docetaxel—head and neck cancer	0.0015	0.00421	CcSEcCtD
Loxapine—Hypersensitivity—Fluorouracil—head and neck cancer	0.00147	0.00412	CcSEcCtD
Loxapine—Dry mouth—Docetaxel—head and neck cancer	0.00147	0.00412	CcSEcCtD
Loxapine—HTR2A—trachea—head and neck cancer	0.00146	0.00359	CbGeAlD
Loxapine—Confusional state—Docetaxel—head and neck cancer	0.00145	0.00407	CcSEcCtD
Loxapine—Oedema—Docetaxel—head and neck cancer	0.00144	0.00404	CcSEcCtD
Loxapine—Shock—Docetaxel—head and neck cancer	0.00142	0.00397	CcSEcCtD
Loxapine—Nervous system disorder—Docetaxel—head and neck cancer	0.00141	0.00396	CcSEcCtD
Loxapine—Pruritus—Fluorouracil—head and neck cancer	0.00141	0.00396	CcSEcCtD
Loxapine—Thrombocytopenia—Docetaxel—head and neck cancer	0.00141	0.00395	CcSEcCtD
Loxapine—Tachycardia—Docetaxel—head and neck cancer	0.0014	0.00394	CcSEcCtD
Loxapine—ADRA2A—thyroid gland—head and neck cancer	0.00136	0.00334	CbGeAlD
Loxapine—Hypotension—Docetaxel—head and neck cancer	0.00134	0.00377	CcSEcCtD
Loxapine—Dizziness—Fluorouracil—head and neck cancer	0.00132	0.0037	CcSEcCtD
Loxapine—Insomnia—Docetaxel—head and neck cancer	0.0013	0.00365	CcSEcCtD
Loxapine—Paraesthesia—Docetaxel—head and neck cancer	0.00129	0.00363	CcSEcCtD
Loxapine—Dyspnoea—Docetaxel—head and neck cancer	0.00128	0.0036	CcSEcCtD
Loxapine—Somnolence—Docetaxel—head and neck cancer	0.00128	0.00359	CcSEcCtD
Loxapine—Vomiting—Fluorouracil—head and neck cancer	0.00127	0.00356	CcSEcCtD
Loxapine—Rash—Fluorouracil—head and neck cancer	0.00126	0.00353	CcSEcCtD
Loxapine—Dermatitis—Fluorouracil—head and neck cancer	0.00126	0.00352	CcSEcCtD
Loxapine—Headache—Fluorouracil—head and neck cancer	0.00125	0.0035	CcSEcCtD
Loxapine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00124	0.00349	CcSEcCtD
Loxapine—Fatigue—Docetaxel—head and neck cancer	0.00124	0.00348	CcSEcCtD
Loxapine—Constipation—Docetaxel—head and neck cancer	0.00123	0.00345	CcSEcCtD
Loxapine—HRH1—head—head and neck cancer	0.00122	0.00302	CbGeAlD
Loxapine—ADRA2A—head—head and neck cancer	0.0012	0.00296	CbGeAlD
Loxapine—SLC6A2—lymph node—head and neck cancer	0.00119	0.00293	CbGeAlD
Loxapine—Feeling abnormal—Docetaxel—head and neck cancer	0.00119	0.00333	CcSEcCtD
Loxapine—Nausea—Fluorouracil—head and neck cancer	0.00118	0.00332	CcSEcCtD
Loxapine—Hypersensitivity—Docetaxel—head and neck cancer	0.00106	0.00297	CcSEcCtD
Loxapine—ADRA2C—lymph node—head and neck cancer	0.00106	0.0026	CbGeAlD
Loxapine—Asthenia—Docetaxel—head and neck cancer	0.00103	0.0029	CcSEcCtD
Loxapine—HTR2A—head—head and neck cancer	0.00102	0.00252	CbGeAlD
Loxapine—Pruritus—Docetaxel—head and neck cancer	0.00102	0.00286	CcSEcCtD
Loxapine—Dizziness—Docetaxel—head and neck cancer	0.000951	0.00267	CcSEcCtD
Loxapine—Vomiting—Docetaxel—head and neck cancer	0.000915	0.00257	CcSEcCtD
Loxapine—Rash—Docetaxel—head and neck cancer	0.000907	0.00255	CcSEcCtD
Loxapine—Dermatitis—Docetaxel—head and neck cancer	0.000906	0.00254	CcSEcCtD
Loxapine—Headache—Docetaxel—head and neck cancer	0.000901	0.00253	CcSEcCtD
Loxapine—HRH1—lymph node—head and neck cancer	0.000857	0.00211	CbGeAlD
Loxapine—Nausea—Docetaxel—head and neck cancer	0.000854	0.0024	CcSEcCtD
Loxapine—ADRA2A—lymph node—head and neck cancer	0.000842	0.00207	CbGeAlD
Loxapine—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	3.02e-05	0.000127	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—IL2—head and neck cancer	3.01e-05	0.000127	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—STAT3—head and neck cancer	3.01e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—PIK3CA—head and neck cancer	3.01e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PTEN—head and neck cancer	3e-05	0.000126	CbGpPWpGaD
Loxapine—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	3e-05	0.000126	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—PIK3CA—head and neck cancer	3e-05	0.000126	CbGpPWpGaD
Loxapine—ADRB1—Signaling by GPCR—AKT1—head and neck cancer	2.99e-05	0.000126	CbGpPWpGaD
Loxapine—HRH2—Signaling Pathways—AKT1—head and neck cancer	2.97e-05	0.000125	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—PIK3CA—head and neck cancer	2.97e-05	0.000125	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—IL2—head and neck cancer	2.97e-05	0.000125	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	2.96e-05	0.000125	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	2.96e-05	0.000124	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—head and neck cancer	2.96e-05	0.000124	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	2.94e-05	0.000124	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PTEN—head and neck cancer	2.93e-05	0.000123	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	2.91e-05	0.000123	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK3—head and neck cancer	2.91e-05	0.000122	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—MAPK1—head and neck cancer	2.91e-05	0.000122	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EGFR—head and neck cancer	2.91e-05	0.000122	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	2.89e-05	0.000122	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK3—head and neck cancer	2.87e-05	0.000121	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	2.86e-05	0.00012	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	2.84e-05	0.00012	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—HRAS—head and neck cancer	2.84e-05	0.00012	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	2.84e-05	0.000119	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	2.8e-05	0.000118	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	2.79e-05	0.000117	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—HRAS—head and neck cancer	2.79e-05	0.000117	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	2.79e-05	0.000117	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—PIK3CA—head and neck cancer	2.79e-05	0.000117	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	2.78e-05	0.000117	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—HRAS—head and neck cancer	2.77e-05	0.000117	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	2.77e-05	0.000117	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MAPK1—head and neck cancer	2.77e-05	0.000117	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EGFR—head and neck cancer	2.77e-05	0.000116	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—head and neck cancer	2.77e-05	0.000116	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	2.77e-05	0.000116	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	2.76e-05	0.000116	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTEN—head and neck cancer	2.75e-05	0.000116	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	2.75e-05	0.000116	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—HRAS—head and neck cancer	2.75e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	2.74e-05	0.000115	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—head and neck cancer	2.74e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	2.74e-05	0.000115	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—head and neck cancer	2.73e-05	0.000115	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MAPK1—head and neck cancer	2.73e-05	0.000115	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EGFR—head and neck cancer	2.73e-05	0.000115	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	2.72e-05	0.000114	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	2.72e-05	0.000114	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	2.71e-05	0.000114	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	2.71e-05	0.000114	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	2.71e-05	0.000114	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	2.7e-05	0.000114	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—head and neck cancer	2.7e-05	0.000114	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—head and neck cancer	2.7e-05	0.000113	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—head and neck cancer	2.7e-05	0.000113	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—head and neck cancer	2.69e-05	0.000113	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—head and neck cancer	2.68e-05	0.000113	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—head and neck cancer	2.68e-05	0.000113	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—head and neck cancer	2.68e-05	0.000113	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—PIK3CA—head and neck cancer	2.67e-05	0.000112	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—head and neck cancer	2.67e-05	0.000112	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—head and neck cancer	2.67e-05	0.000112	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CCND1—head and neck cancer	2.67e-05	0.000112	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	2.66e-05	0.000112	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	2.65e-05	0.000111	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—head and neck cancer	2.64e-05	0.000111	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—head and neck cancer	2.63e-05	0.000111	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—head and neck cancer	2.63e-05	0.000111	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	2.63e-05	0.000111	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—head and neck cancer	2.62e-05	0.00011	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	2.62e-05	0.00011	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—head and neck cancer	2.62e-05	0.00011	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK3—head and neck cancer	2.62e-05	0.00011	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CCND1—head and neck cancer	2.62e-05	0.00011	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CCND1—head and neck cancer	2.61e-05	0.00011	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	2.61e-05	0.00011	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CCND1—head and neck cancer	2.6e-05	0.000109	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	2.59e-05	0.000109	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—HRAS—head and neck cancer	2.58e-05	0.000109	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—head and neck cancer	2.58e-05	0.000109	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—HRAS—head and neck cancer	2.58e-05	0.000109	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CCND1—head and neck cancer	2.57e-05	0.000108	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—head and neck cancer	2.57e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	2.57e-05	0.000108	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—HRAS—head and neck cancer	2.56e-05	0.000108	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	2.56e-05	0.000108	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—head and neck cancer	2.55e-05	0.000107	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	2.54e-05	0.000107	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	2.54e-05	0.000107	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	2.53e-05	0.000106	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—head and neck cancer	2.53e-05	0.000106	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—head and neck cancer	2.52e-05	0.000106	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	2.52e-05	0.000106	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—head and neck cancer	2.52e-05	0.000106	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—HRAS—head and neck cancer	2.51e-05	0.000106	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—head and neck cancer	2.51e-05	0.000106	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—head and neck cancer	2.51e-05	0.000106	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	2.5e-05	0.000105	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	2.5e-05	0.000105	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	2.49e-05	0.000105	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MAPK1—head and neck cancer	2.49e-05	0.000105	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—head and neck cancer	2.49e-05	0.000105	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—head and neck cancer	2.49e-05	0.000105	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	2.48e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	2.47e-05	0.000104	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—HRAS—head and neck cancer	2.47e-05	0.000104	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	2.47e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	2.47e-05	0.000104	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	2.47e-05	0.000104	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—head and neck cancer	2.46e-05	0.000104	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	2.46e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—head and neck cancer	2.45e-05	0.000103	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—head and neck cancer	2.45e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—head and neck cancer	2.44e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—HRAS—head and neck cancer	2.44e-05	0.000103	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—head and neck cancer	2.42e-05	0.000102	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	2.42e-05	0.000102	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	2.42e-05	0.000102	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—head and neck cancer	2.4e-05	0.000101	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—head and neck cancer	2.39e-05	0.000101	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	2.39e-05	0.0001	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	2.38e-05	0.0001	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	2.38e-05	0.0001	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—head and neck cancer	2.38e-05	0.0001	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	2.37e-05	9.98e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	2.37e-05	9.97e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	2.37e-05	9.97e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—HRAS—head and neck cancer	2.33e-05	9.82e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—head and neck cancer	2.33e-05	9.78e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—head and neck cancer	2.32e-05	9.77e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	2.3e-05	9.69e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	2.3e-05	9.69e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	2.3e-05	9.69e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—head and neck cancer	2.3e-05	9.68e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—head and neck cancer	2.29e-05	9.65e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	2.29e-05	9.62e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—head and neck cancer	2.28e-05	9.6e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—head and neck cancer	2.28e-05	9.59e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—head and neck cancer	2.28e-05	9.58e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	2.27e-05	9.56e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	2.27e-05	9.54e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	2.27e-05	9.54e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—head and neck cancer	2.27e-05	9.53e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	2.26e-05	9.52e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—head and neck cancer	2.26e-05	9.52e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—head and neck cancer	2.26e-05	9.5e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—head and neck cancer	2.25e-05	9.47e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	2.25e-05	9.45e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—head and neck cancer	2.24e-05	9.44e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—head and neck cancer	2.24e-05	9.44e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	2.24e-05	9.42e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—HRAS—head and neck cancer	2.22e-05	9.35e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—head and neck cancer	2.22e-05	9.35e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—head and neck cancer	2.22e-05	9.32e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	2.22e-05	9.32e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK3—head and neck cancer	2.2e-05	9.25e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—HRAS—head and neck cancer	2.19e-05	9.23e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—head and neck cancer	2.18e-05	9.17e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	2.16e-05	9.1e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—head and neck cancer	2.16e-05	9.09e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK3—head and neck cancer	2.16e-05	9.08e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—head and neck cancer	2.15e-05	9.05e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	2.15e-05	9.05e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK3—head and neck cancer	2.14e-05	9.02e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	2.14e-05	9.01e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK3—head and neck cancer	2.12e-05	8.93e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	2.12e-05	8.91e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—head and neck cancer	2.12e-05	8.91e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MAPK1—head and neck cancer	2.09e-05	8.8e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—head and neck cancer	2.09e-05	8.79e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—head and neck cancer	2.09e-05	8.79e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	2.08e-05	8.75e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—head and neck cancer	2.07e-05	8.71e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	2.07e-05	8.69e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—head and neck cancer	2.06e-05	8.67e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	2.06e-05	8.66e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	2.06e-05	8.66e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	2.06e-05	8.65e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	2.06e-05	8.65e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MAPK1—head and neck cancer	2.05e-05	8.64e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—head and neck cancer	2.05e-05	8.64e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	2.05e-05	8.61e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—head and neck cancer	2.05e-05	8.61e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MAPK1—head and neck cancer	2.04e-05	8.58e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—head and neck cancer	2.04e-05	8.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MAPK1—head and neck cancer	2.02e-05	8.5e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—head and neck cancer	2.02e-05	8.5e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	2.01e-05	8.48e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	2.01e-05	8.47e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	2e-05	8.41e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—head and neck cancer	2e-05	8.41e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—HRAS—head and neck cancer	2e-05	8.41e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.99e-05	8.37e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	1.98e-05	8.33e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	1.97e-05	8.28e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	1.97e-05	8.28e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—head and neck cancer	1.96e-05	8.26e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—head and neck cancer	1.95e-05	8.22e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—head and neck cancer	1.94e-05	8.17e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—head and neck cancer	1.94e-05	8.15e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—head and neck cancer	1.93e-05	8.14e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—HRAS—head and neck cancer	1.91e-05	8.04e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—head and neck cancer	1.9e-05	8.01e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.9e-05	8e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	1.87e-05	7.87e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	1.87e-05	7.87e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	1.85e-05	7.78e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	1.82e-05	7.66e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	1.81e-05	7.63e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	1.79e-05	7.51e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	1.78e-05	7.49e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	1.78e-05	7.47e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—head and neck cancer	1.77e-05	7.45e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—head and neck cancer	1.77e-05	7.43e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—head and neck cancer	1.76e-05	7.38e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—head and neck cancer	1.75e-05	7.37e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	1.75e-05	7.36e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	1.75e-05	7.35e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—head and neck cancer	1.73e-05	7.28e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—head and neck cancer	1.73e-05	7.27e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—head and neck cancer	1.72e-05	7.25e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—head and neck cancer	1.72e-05	7.23e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—head and neck cancer	1.71e-05	7.2e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—head and neck cancer	1.7e-05	7.13e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—head and neck cancer	1.69e-05	7.11e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—head and neck cancer	1.69e-05	7.1e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	1.68e-05	7.07e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—HRAS—head and neck cancer	1.68e-05	7.06e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	1.65e-05	6.95e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—HRAS—head and neck cancer	1.65e-05	6.93e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—HRAS—head and neck cancer	1.64e-05	6.91e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—HRAS—head and neck cancer	1.64e-05	6.89e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	1.63e-05	6.87e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	1.62e-05	6.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—HRAS—head and neck cancer	1.62e-05	6.82e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	1.62e-05	6.8e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	1.61e-05	6.76e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—head and neck cancer	1.59e-05	6.68e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—head and neck cancer	1.57e-05	6.61e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	1.5e-05	6.32e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—head and neck cancer	1.48e-05	6.24e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	1.46e-05	6.14e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—head and neck cancer	1.46e-05	6.12e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—head and neck cancer	1.45e-05	6.1e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—head and neck cancer	1.45e-05	6.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—head and neck cancer	1.43e-05	6.02e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	1.43e-05	6.01e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	1.33e-05	5.58e-05	CbGpPWpGaD
